PYLARIFY TruVu™ (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...

TD Cowen 46th Annual Health Care Conference March 4, 2026 9:50 AM ESTCompany ParticipantsMartin Hogan - Senior Director ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...

Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...

For more information about Candel, visit: www.candeltx.com.

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

Merve Ceylan is a dietitian and health writer with four years of experience writing for companies in the nutrition and health industry. Some foods and drinks can worsen prostate health. Saturated fats ...

The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.